- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00563953
Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)
A Phase II, Open-Label, Multicenter Clinical Trial of Pegylated Liposomal Doxorubicin (Caelyx®) as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease or Age Over 65 Years.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a phase II, uncontrolled, open label, multicenter study of a primary chemotherapy regimen consisting of four cycles of liposomal pegylated doxorubicine 35 mg/m² IV plus cyclophosphamide 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery in breast cancer patients at risk of developing anthracycline-induced cardiotoxicity.
Surgery (tumorectomy, quadrantectomy, or mastectomy plus lymphadenectomy) will be performed 2 to 5 weeks after the last primary chemotherapy infusion.
Patients with > 10% of hormone receptor-positive cells will receive appropriate hormone therapy according to menopausal status.
Patients treated with breast-conserving surgery will receive radiation therapy to the mammary gland.
Patients with T4 tumors or significant axillary involvement (≥ ypN2) will receive radiation therapy to the breast or chest wall and to the lymph node chains.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Barcelona, Spanien, 08025
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Lleida, Spanien, 25198
- Hospital Universitari Arnau de Vilanova
-
Madrid, Spanien, 28041
- Hospital Universitario 12 de Octubre
-
Murcia, Spanien, 30008
- Hospital Universitario Morales Meseguer
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
- Institut Català d'Oncologia
-
-
Illes Balears
-
Palma de Mallorca, Illes Balears, Spanien, 07198
- Hospital Son Llatzer
-
-
Tarragona
-
Reus, Tarragona, Spanien, 42301
- Hospital Universitario Sant Joan de Reus
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed invasive breast cancer (tumor > 2 cm).
- Estrogen receptor-negative or -weakly positive tumors (less than 50% of cells), as evaluated using IHC.
- Risk factors for developing anthracycline-induced cardiomyopathy.
Exclusion Criteria:
- Severe heart failure (NYHA Class III or IV) .
- Metastatic disease.
- LVEF < 45%.
- Pregnant or breast-feeding patients.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
|
Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Pathological complete response (pCR). pCR is defined as the absence of invasive cancer in the surgical breast specimen. This definition includes evidence of carcinoma in situ only.
Tidsram: At surgery.
|
At surgery.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Clinical response rate (complete plus partial responses). Clinical response will be assessed by imaging using the WHO criteria.
Tidsram: Before and after treatment with paclitaxel.
|
Before and after treatment with paclitaxel.
|
Breast-conserving surgery: tumorectomy or quadrantectomy with or without lymphadenectomy versus mastectomy.
Tidsram: At surgery.
|
At surgery.
|
Axillary node involvement after primary chemotherapy.
Tidsram: At surgery.
|
At surgery.
|
Left ventricular ejection fraction measured by echocardiography or MUGA.
Tidsram: At baseline, every 2 doxorubicine cycles and before surgery.
|
At baseline, every 2 doxorubicine cycles and before surgery.
|
Cardiac sign/symptom questionnaire.
Tidsram: At baseline, every 2 doxorubicine cycles and before surgery.
|
At baseline, every 2 doxorubicine cycles and before surgery.
|
Relapse-free survival at 5 years after surgery and overall survival at 5 years after study entry.
Tidsram: Until 5 years after surgery.
|
Until 5 years after surgery.
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Miguel Gil, MD, Institut Català d'Oncologia
Publikationer och användbara länkar
Allmänna publikationer
- Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martinez E, Martinez-Janez N, Mele M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.
- Gil MJ, Bellet MC, Llombart, Ojeda B, Manso L, Mesia C, Morales S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, Baselga J. Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study. Cancer Research 71(24 Suppl.): 403s, 2011.(CTRC-AACR San Antonio Breast Cancer Symposium)
- Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, Saura C, Fernandez-Ortega A, Garcia-Martinez E, Martinez-Janez N, Mele M, Villagrasa P, Celiz P, Perez Martin X, Ciruelos E, Pernas S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol. 2021 Jul 9;11:645026. doi: 10.3389/fonc.2021.645026. eCollection 2021.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SOLTI0702
- 2007-001428-11 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på Liposomal pegylated doxorubicine
-
Marval Pharma Ltd.AvslutadFriska volontärerFörenta staterna
-
Grupo Español de Investigación en Cáncer de OvarioPharmaMarAvslutad
-
National Cancer Institute (NCI)AvslutadÅterkommande fallopian Tube Carcinom | Återkommande äggstockscancer | Återkommande primärt peritonealt karcinom | Återkommande bröstkarcinom | Östrogenreceptornegativ | HER2/Neu negativ | Progesteronreceptornegativ | Trippelnegativt bröstkarcinom | Manligt bröstkarcinom | Steg IV Bröstcancer AJCC v6 och v7Förenta staterna
-
National Cancer Institute (NCI)AvslutadDS Steg I Plasmacellmyelom | DS Steg II Plasmacellmyelom | DS Steg III PlasmacellmyelomFörenta staterna
-
Ayana Pharma Ltd.,Lambda Therapeutic Research Ltd.AvslutadÅterkommande äggstockscancerIndien
-
Second Affiliated Hospital, School of Medicine,...RekryteringBröstcancer | Effektivitet | Säkerhet | Liposomal doxorubicin | Postoperativ adjuvansbehandlingKina
-
Peking University People's HospitalHunan Cancer Hospital; Peking University Cancer Hospital & Institute; Peking... och andra samarbetspartnersOkänd
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)AvslutadÅterkommande fallopian Tube Carcinom | Återkommande äggstockscancer | Återkommande primärt peritonealt karcinom | Ovarialt klarcelligt cystadenocarcinom | Äggstocksendometrioid adenokarcinom | Ovarialt seromucinöst karcinom | Ovarialt seröst cystadenocarcinom | Ovarialt odifferentierat karcinomFörenta staterna
-
Sequus PharmaceuticalsAvslutadHIV-infektioner | Sarkom, KaposiFörenta staterna
-
Sequus PharmaceuticalsAvslutadHIV-infektioner | Sarkom, KaposiFörenta staterna